Abstract
There is active debate regarding how GABAergic function changes during seizure initiation and propagation, and whether interneuronal activity drives or impedes the pathophysiology. Here, we track cell-type specific firing during spontaneous human seizures to identify neocortical mechanisms of inhibitory failure. Fast-spiking interneuron activity was maximal over 1 second before equivalent excitatory increases, and showed transitions to out-of-phase firing prior to local tissue becoming incorporated into the seizure-driving territory. Using computational modeling, we linked this observation to transient saturation block as a precursor to seizure invasion, as supported by multiple lines of evidence in the patient data. We propose that transient blocking of inhibitory firing due to selective fast-spiking interneuron saturation—resulting from intense excitatory synaptic drive—is a novel mechanism that contributes to inhibitory failure, allowing seizure propagation.
Competing Interest Statement
S.A.S. is a consultant for Boston Scientific, Zimmer Biomet, Neuropace, Koh Young, Sensoria Therapeutics and Varian Medical, and is co-founder of Motif Neurotech. The other authors report no competing interests.
Funding Statement
The authors acknowledge funding from R01 NS084142 and R01 NS110669 (C.A.S.), and University of Chicago MSTP Training Grant T32GM007281 and F31NS127493 (S.S.D.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures were approved by the respective Institutional Review Boards of Columbia University Medical Center, University of Utah and Massachusetts General Hospital/Brigham & Women’s Hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The raw data that support the findings of this study are available upon reasonable request from the corresponding author. To protect the privacy of research participants, they are not publicly accessible.
